4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-13

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 6, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical data from the ongoing IMR-687 Phase 2a open label extension (OLE) clinical trial in adult patients with sickle cell disease (SCD) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020. The presentation (abstract #1726), titled “Benefits and Safety of Long-Term Use of IMR-687 as Monotherapy or in Combination with a Stable Dose

-- Combined Company to Trade on Nasdaq Under Ticker "ELVN" ---- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced the results of the special meeting of its stockholders held on February 22, 2023. At the special meeting, Imara's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Imara's common stock to the stockholders of Enliven Therapeutics, Inc. ("Enliven") pursuant to the terms of the Agreement and Plan of Merger, dated as of October 13, 2022, pursuant to which a direct, wholly-owned subsidiary of Imara will merge with and into

NEW YORK, NY / ACCESSWIRE / November 23, 2022 / Lifshitz Law PLLC:Imara Inc. (NASDAQ:IMRA)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of IMRA and Enliven Therapeutics, Inc.If you are an IMRA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or email at [email protected] Solutions, Inc. (NASDAQ:AGFS)Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AGFS to Paine Schwartz Partners for $3.00 per share in cash.If you a

Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat population Interim results in Forte trial for beta-thalassemia demonstrated no meaningful benefit in transfusion burden or improvement in most disease-related biomarkers Tovinontrine was generally well-tolerated across studies Both Phase 2b clinical trials and further development of tovinontrine in sickle cell and beta-thalassemia to be discontinued BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA) today announced results from interim analyses of its Ardent Phase 2b clinica

Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ardent Phase 2b trial in sickle cell disease to reductions in annualized rate of VOCs at written request of the FDA Added clinical indication for tovinontrine to include the treatment of HFpEF; anticipate first subject dosing in Phase 2 trial in second quarter of 2022 Expanded pipeline with addition of IMR-261, an oral, clinic-ready Nrf2 activator with potential indications in hemoglobin and iron overload disorders Company to host conference call and live webcast today at 8:30 AM ET BO

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website. The conference call can be accessed by dialing +1 (833) 519-1307 (U.S. domestic) or (914) 800

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.  A replay of the webcast will be archived on the "Events and Presentations" section of Imara's website. About ImaraImara Inc. is a clinical-stage biotechnology company dedicated to develop

Expanding patient base and potential of Imara's small molecule oral inhibitor of phosphodiesterase-9 (PDE9) alongside hemoglobin disorders Phase 2 trial aims to select HFpEF patients with enriched PDE9 expressionfor targeted approach to a heterogeneous disease Study initiation planned for second quarter of 2022 BOSTON, Jan. 25, 2022 (GLOBE NEWSWIRE) --  Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application

BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022. A webcast of the pre-recorded presentation will be made available at 7:00 AM ET on Monday, January 10th and will be available under "Events and Presentations" in the Investors section of the company's website at www.imar

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 activation of Nrf2 increases HbF and F-cells, reduces VOCs and reduces markers of adhesion and hemolysis Beta-thalassemia mouse model shows IMR-261 increases hemoglobin and improves ineffective erythropoiesis BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today a

Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

Citigroup resumed coverage of IMARA with a rating of Buy and set a new price target of $30.00

Morgan Stanley reiterated coverage of Imara with a rating of Overweight and set a new price target of $33.00 from $34.00 previously

SVB Leerink reiterated coverage of IMARA with a rating of Outperform and set a new price target of $42.00 from $59.00 previously

Morgan Stanley reiterated coverage of IMARA with a rating of Overweight and set a new price target of $34.00 from $35.00 previously

Morgan Stanley reiterated coverage of Imara with a rating of Overweight and set a new price target of $34.00 from $35.00 previously

SVB Leerink reiterated coverage of Imara with a rating of Outperform and set a new price target of $42.00 from $59.00 previously

U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. The Dow traded up 1.50% to 31,547.65 while the NASDAQ rose 1.04% to 10,972.47. The S&P 500 also rose, gaining, 1.38% to 3,804.48. Also check this: Market Volatility Decreases As Dow Jumps More Than 700 Points Leading and Lagging Sectors Health care shares climbed 2.1% on Monday. Leading the sector was strength from Vaxcyte, Inc. (NASDAQ:PCVX) and IMARA Inc. (NASDAQ:IMRA). In trading on Monday, materials shares fell by 0.3%. Top Headline   The S&P Global manufacturing PMI dropped to 49.9 in October from 52 in September, down from market estimates of 51. US services PM

The Dow Jones dropped by around 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3 NGM Biopharmaceuticals The Trade: NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Director David Goeddel V bought a total of 130,000 shares at an average price of $3.56. To acquire these shares,

Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million. Moleculin Biotech (NASDAQ:MBRX) shares increased by 9.34% to $1.04. The market value of their outstanding shares is at $29.7 million. Biocept (NASDAQ:BIOC) stock rose 8.35% to $0.83. The company's market cap stands at $14.0 million. AquaBounty Technologies (NASDAQ:AQB) shares moved upwards by 8.13% to $0.64. The market value of their outstanding shares is at $45.4 million. SINTX Technologies (NASDAQ:SINT) stock moved upwards by 7.2% to $0.12. This security traded at a volume of 11.7 million shares come close,

Gainers COMSovereign Holding Corp. (NASDAQ:COMS) shares jumped 170.1% to close at $0.1194 on Tuesday after gaining 4% on Monday. Akouos, Inc. (NASDAQ:AKUS) shares surged 88.2% to close at $13.19 on Tuesday. Eli Lilly And Co (NYSE:LLY) agreed to acquire Akouos for a 78% premium over Monday’s closing price of $7.01. Rubicon Technologies, Inc. (NYSE:RBT) climbed 58.2% to close at $1.74. Helbiz, Inc. (NASDAQ:HLBZ) climbed 58.1% to close at $0.4211. Helbiz CEO Salvatore Palella recently acquired a total of 200,000 shares at an average price of $0.25. Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) jumped 44.4% to close at $2.73 after the company announced plans to initiate a second clinical tri

Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million. Milestone Pharmaceuticals (NASDAQ:MIST) shares increased by 32.03% to $11.21. The market value of their outstanding shares is at $336.4 million. Ayala Pharmaceuticals (NASDAQ:AYLA) shares rose 26.08% to $1.16. The company's market cap stands at $17.1 million. Scopus BioPharma (NASDAQ:SCPS) shares moved upwards by 22.39% to $0.3. The market value of their outstanding shares is at $6.3 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 19.75% to $0.17. The market value of their outstanding shares is at $20.1 million.

Gainers Agrify Corporation (NASDAQ:AGFY) climbed 53.8% to close at $1.45. FedNat Holding Company (NASDAQ:FNHC) gained 48% to settle at $0.52. IMARA Inc. (NASDAQ:IMRA) shares climbed 46.9% to close at $3.79 after the company, along with Enliven Therapeutics, announced a merger agreement to combine the two companies in an all-stock transaction. Avenue Therapeutics, Inc. (NASDAQ:ATXI) jumped 37% to close at $3.33. Avenue Therapeutics recently priced a roughly 3.6 million unit offering at $3.30 per unit. MicroCloud Hologram Inc. (NASDAQ:HOLO) gained 27.7% to settle at $2.58. Gravitas Education Holdings, Inc. (NASDAQ:GEHI) shares surged 27.1% to close at $19.06. Marker Therapeutics, Inc.

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 375 points on Friday. The Dow traded down 1.25% to 29,662.76 while the NASDAQ fell 2.68% to 10,363.83. The S&P 500 also fell, dropping, 2.10% to 3,592.94. Also check this: Market Volatility Declines Following US Inflation Data Leading and Lagging Sectors Health care shares fell by just 0.7% on Friday. Leading the sector was strength from Reata Pharmaceuticals, Inc. (NASDAQ:RETA) and Zymeworks Inc. (NASDAQ:ZYME). In trading on Friday, energy shares dipped by 3.5%. Top Headline   JPMorgan Chase & Co. (NYSE:JPM) posted better-than-expected earnings for its third quarter on Friday. JPMorgan Cha

Imara's (NASDAQ:IMRA) short percent of float has fallen 13.5% since its last report. The company recently reported that it has 1.37 million shares sold short, which is 9.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 0.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp

Gainers Avenue Therapeutics (NASDAQ:ATXI) stock rose 38.8% to $3.37 during Friday's regular session. Trading volume for Avenue Therapeutics's stock is 49.0 million as of 13:30 EST. This is 1901.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.9 million. Imara (NASDAQ:IMRA) shares rose 35.65% to $3.5. The current volume of 31.3 million shares is 1186.7% of Imara's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $92.0 million. Marker Therapeutics (NASDAQ:MRKR) stock moved upwards by 22.58% to $0.38. As of 13:30 EST, this security is trading at a vol